amaxa eNews #2   Issue: amaxa eNews #1 amaxa eNews #2 amaxa eNews #3 amaxa eNews #4 amaxa eNews #5 Article: Overview Review Product Information Application Note Presentation Meetings & Shows Order more Info Related FAQs Related Citations FAQs on the Nucleofection of Stem Cells Are there any effects on the differentiation of neural stem cells following nucleofection®? Can calcium influx issues affect viability or differentiation in Stem Cells? Is it possible to use frozen primary CD34+ hematopoietic stem cells for nucleofection? What is a Neural Stem Cell (NSC)? Do NSCs (Neural Stem Cells) differentiate in co-culture with astrocytes? I routinely culture neural stem cells as neurospheres. Can these be transfected by nucleofection®? Can calcium influx issues affect viability of human Mesenchymal Stem Cells (hMSC)? Do you have a kit for murine embryonic stem cells (mES)? I observed high mortality rates in mES cells after Nucleofection with a Cre recombinase expression vector. How can I increase the viability? For more FAQs browse our FAQ database.        More Information If your question is not listed here please do not hesitate to contact our Scientific Support Team:   Europe/World  USA   phone  +49(0)221-99199-400  (888) 632-9110   fax  +49(0)221-99199-499  (888) 632-9112   e-mail  scientific-support.amaxa@lonza.com  scientific-support.US.amaxa@lonza.com  Subscribe Subscribe here to receive future issues of amaxa eNews. Invite a friend Recommend amaxa's eNews to a friend or colleague.   amaxa's Nucleofection Process, Nucleofector Device and Nucleofector Solutions are covered by PCT Applications PCT/EP01/07348, PCT/DE02/01489, PCT/DE02/01483, and other pending patents, and domestic or foreign applications corresponding thereto. amaxa, Nucleofector, Nucleofection and pmaxGFP are trademarks of amaxa AG. GlutaMAX is a trademark of Invitrogen. Other product and company names mentioned herein are the trademarks of their respective owners. amaxa disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, safety, or suitability of the information provided in this e-newsletter for any particular purpose. Any use of the information contained on any page of this e-newsletter is evidence of agreement with these terms of use.